Adverse event profile with once-monthly oral ibandronate: The MOBILE study long-term extension.

被引：0
|
作者：
Silverman, S.
Emkey, R.
Reginster, J. Y.
Lorenc, R.
Hughes, C.
Kendler, D.
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Radiant Res, Wyomissing, PA USA
[3] Univ Liege, B-4000 Liege, Belgium
[4] Childrens Mem Inst, Warsaw, Poland
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Univ British Columbia, Osteoporosis Res Ctr, Vancouver, BC V5Z 1M9, Canada
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S418 / S418
页数：1
相关论文
共 50 条
  • [21] Once-monthly dosing of oral ibandronate is highly efficacious: 2-year results from mobile
    Reginster, J. -Y.
    Stakkestad, J. A.
    Lorenc, R.
    Hughes, C.
    Mairon, N.
    Coutant, K.
    Adami, S.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S64 - S65
  • [22] Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study
    Fleseriu, Maria
    Petersenn, Stephan
    Biller, Beverly M. K.
    Kadioglu, Pinar
    De Block, Christophe
    T'Sjoen, Guy
    Vantyghem, Marie-Christine
    Tauchmanova, Libuse
    Wojna, Judi
    Roughton, Michael
    Lacroix, Andre
    Newell-Price, John
    CLINICAL ENDOCRINOLOGY, 2019, 91 (06) : 776 - 785
  • [23] Once-monthly oral ibandronate is at least as effective as daily oral ibandronate in postmenopausal osteoporosis: 2-year findings from MOBILE.
    McClung, MR
    Drezner, MK
    Reginster, JY
    Bolognese, M
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Delmas, PD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S395 - S395
  • [24] Once-monthly oral ibandronate - Effective treatment for postmenopausal osteoporosis (PMO): MOBILE 2-year results
    Miller, P
    Drezner, M
    Lewiecki, M
    Bolognese, M
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 803 - 803
  • [25] Patient preference for once-monthly oral ibandronate and weekly oral alendronate in postmenopausal osteoporosis: The BALTO II study
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S127 - S128
  • [26] The BALTO II study: Patient preference for once-monthly oral ibandronate and weekly oral alendronate in postmenopausal osteoporosis
    Minne, H.
    Bourgeois, P.
    Devas, V.
    Masanauskaite, D.
    Minic, B.
    Licata, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 423 - 423
  • [27] Efficacy and Tolerability of Once-Monthly Oral Ibandronate (150 mg) and Once-Weekly Oral Alendronate (70 mg): Additional Results From the Monthly Oral Therapy With Ibandronate for Osteoporosis Intervention (MOTION) Study
    Emkey, Ronald
    Delmas, Pierre D.
    Bolognese, Michael
    Borges, Lindolfo C.
    Cosman, Felicia
    Ragi-Eis, Sergio
    Recknor, Christopher
    Zerbini, Cristiano A.
    Neate, Colin
    Sedarati, Farhad
    Epstein, Solomon
    CLINICAL THERAPEUTICS, 2009, 31 (04) : 751 - 761
  • [28] Response to once-monthly and daily oral ibandronate in women with postmenopausal osteoporosis: 2-year findings from mobile
    Stepan, J. J.
    Kendler, D.
    Sedarati, F.
    Burdeska, A.
    Hughes, C.
    Lorenc, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 429 - 429
  • [29] Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate is similar in postmenopausal osteoporosis:: 1-year results from mobile
    Adami, S
    Tankó, LB
    Nuti, R
    Leigh, C
    Mairon, N
    Sedarati, F
    Reginster, JY
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 364 - 364
  • [30] Once-monthly oral ibandronate is safe and well tolerated in women with postmenopausal osteoporosis: MOBILE 2-year analysis.
    Lewiecki, EM
    Emkey, R
    Adami, S
    Rowell, L
    Mairon, N
    Bonvoisin, B
    Felsenberg, D
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S285 - S285
12345